There are almost forty (40) companies that research the treatment of mental illnesses based on the use of one or more of ten (10) different psychedelic compound-based substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). The munKNEE Psychedelic Drug Stocks Index tracks the performance of the six (6) largest such psychedelic stocks by market capitalization and below are their performances year-to-date (February 16th), in descending order:

1. Mind Medicine (MNMD): UP 81.7% YTD 
   • is in Phase 2 for the treatment of generalized anxiety disorder, attention deficit hyperactivity disorder and chronic pain;
   • is developing a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder;
   • has completed Phase 1 for the treatment of opioid withdrawal with an a3ß4 nicotinic cholinergic receptor antagonist.
2. Cybin (CYBN): UP 51.7% YTD
   • is focused on the treatment of:
     • major depressive and alcohol use disorders with a deuterated psilocybin analog,
     • anxiety disorders with deuterated dimethyltryptamine and
     • neuroinflammation with a phenethylamine derivative; and
   • has developed EMBARK, a psychedelic-assisted psychotherapy.
3. Compass Pathways (CMPS): UP 16.8% YTD
   • has completed Phase IIb clinical trials for the treatment of Treatment-Resistant Depression with psilocybin therapy and
   • is in Phase II clinical trials for the treatment of post-traumatic stress disorder.
4. Seelos (SEEL): UP 13.8% YTD
   • its therapeutic candidates include:
     • an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders;
     • a protein stabilizer for the treatment of amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome;
     • a partial dopamine agonist for the treatment of patients with Parkinson's Disease.
   • its preclinical programs include:
     • an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's Disease;
     • an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications;
     • an oral histamine H3A receptor antagonist for narcolepsy and related disorders;
     • an injectable therapy for post-operative pain management. 
5. GH Research (GHRS): UP 0.8% YTD
   • is focused on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD);
   • has completed two Phase 1 clinical trials and Phase 1/2 clinical trials in patients with TRD; 
   • is in preclinical development trials with both injectable and intranasal 5-MeO-DMT product candidates.
6. Atai (ATAI): DOWN 29.8% YTD
   • its therapeutic candidates include:
     • a subcutaneous formulation of R-ketamine, a formulation of N,N-dimethyltryptamine and a formulation of Salvinorin A for treating treatment-resistant depression;
     • oral formulations of ibogaine, deuterated mitragynine and noribogaine for treating opioid use disorder;
     • an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder;
     • an oral formulation of a deuterated version of etifoxine for the treatment of generalized anxiety disorder; and
     • a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries.

In total, the Index value was DOWN only 1.2% this week so it is now UP 11.5% YTD.

More By This Author:

4 Of The 5 Largest Canadian Cannabis LPs Are Still Up YTD
Cannabis Portfolio Contest Update: YTD Performances Range From +12.7% To -10.0%
"Rags-To-Riches" Portfolio Down 8% Last Week